Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Advaccine-announced-the completion-of-more-than-200M-yuan-in-Series-B-financing. Investors in this round include new and existing shareholders such as Jenner LLP, Jingwei Venture Capital, Lianxin Capital, and Star Capital.
2020-09-30 08:39Investment community sybil
The investment community (ID: pedaly2012) reported on September 30 that Advaccine announced that it has completed more than 200 million yuan in Series B financing, which is another after the merger of Sauer Biotech in September this year. Milestone events. Round investors include medical Jenner (Jenner LLP), Matrix Partners , linking the new capital of old and new shareholders, capital and other stars.

Dr. Bin Wang, co-founder and chief scientist of Ai Diweixin, said: “As the third-generation nucleic acid vaccine, DNA vaccines have obtained a large number of positive human clinical data, both in terms of safety and effectiveness. Proof of concept, and because of its relatively simple production and storage conditions, it has the advantage of large-scale industrial application. Ai Di Weixin has the world-class DNA plasmid large-scale production technology. After the merger of S.A. Equipped with high-standard hardware facilities for the mass production of vaccines. We are very confident in the upcoming late-stage clinical trials of the new crown DNA vaccine, as well as Ai Di Weixin’s domestic and foreign partners. I believe that with Ai Di Weixin B With the completion of the round of financing, the clinical research and industrialization of DNA vaccines will be further accelerated and moved to a new level."

It is understood that Advaccine is a global clinical stage vaccine technology company driven by innovative technology. With an internationally leading technology platform for immune tolerance and immune activation, it focuses on the development and application of innovative vaccine technologies such as genetic engineering vaccines, DNA vaccines, and new vaccine adjuvants. It is also a leading company in the field of DNA vaccines in China.

Ai Diweixin's research varieties include novel coronavirus preventive vaccine (new coronavirus DNA vaccine), respiratory syncytial virus pneumonia preventive vaccine (recombinant protein RSV vaccine), recombinant protein hepatitis B therapeutic vaccine, etc., all have broad unsatisfactory Clinical and market demand. Ai Diweixin's new coronavirus DNA vaccine is a key vaccine technology research project for the national joint prevention and control of new coronary pneumonia. It has now entered the clinical stage in China, and clinical trials are being carried out simultaneously in the United States. The new respiratory syncytial virus (RSV) pneumonia vaccine developed by Ai Diweixin has been supported by the national "Twelfth Five-Year" major new drug creation project. Phase II clinical research is being initiated in Australia, and the development progress is leading the world.
https://translate.googleusercontent.com/translate_c?depth=1&hl=en&nv=1&pto=aue&rurl=translate.google.com&sl=auto&sp=nmt4&tl=en&u=https://m.pedaily.cn/news/460573&usg=ALkJrhhLD9dXI7XJUy1UctBwJImJlw5_pA

Translated from http://news.pedaily.cn/202009/460573.shtml